AR101 Real-World Open-Label Extension Study

Key Inclusion Criteria:

• Received AR101 in study ARC007
• Completed the ARC007 study
• Use of effective birth control by sexually active female subjects of childbearingpotential

Key Exclusion Criteria:

• Developed a clinically significant change in health status during the ARC007 studywhich in the opinion of the investigator would make the subject unsuitable forparticipation in this study.
• Receiving a prohibited medication or anticipated use of a prohibited medication [e.g.,angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers or calciumchannel blockers], any monoclonal antibody, any investigational peanut immunotherapy,or any other immunomodulatory therapy.
• Currently in the build-up phase of immunotherapy for any nonfood allergen.
• Currently participating in any other interventional clinical study outside of theARC007 study that was just completed.